Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
(Brief Background) Let me give you quick background for context
Problems get caught early because someone is genuinely watching
NICE guidance (NG28) recommends GLP-1 receptor agonists as a treatment option for adults with type 2 diabetes when: Triple therapy with metformin and two other oral drugs is not effective, not tolerated or contraindicated The person has a BMI of 35 kg/m or higher (adjust accordingly for people from particular ethnic groups) and specific psychological or other medical problems associated with obesity The person has a BMI lower than 35 kg/m and insulin would have significant occupational implications, or weight loss would benefit other significant obesity-related comorbidities GLP-1 receptor agonists may also be considered in combination with insulin therapy in specialist care settings Beyond glycaemic control, specific GLP-1 receptor agonists offer significant cardiovascular benefits
This quantity is the maintenance amount for Wegovy, used for weight management
Following subcutaneous administration, tirzepatide reaches peak plasma concentrations (Tmax) in 8 to 72 hours, with steady-state concentrations achieved after approximately 4 weeks of once-weekly dosing
